Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 12, 2026 at 12:07 AM GMT+3 2 min read

HBIO +0.65%

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Execution and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Delivered 11% revenue growth driven by robust demand from CRO customers and double-digit expansion in telemetry and CMT portfolios.
Attributed strong performance in China to the 'Made in China' localization initiative, specifically the launch of the localized BTX electroporation line.
Reported a slight gross margin compression due to a mix shift toward CMT products and China-based sales, which carry lower relative margins than the core portfolio.
Expanded recurring revenue to 55% of total sales, leveraging a growing installed base of SoHo and BTX platforms to drive high-margin consumable and software sales.
Optimized commercial alignment under new leadership to focus on high-growth New Product Innovation (NPI) platforms and bioprocessing opportunities.
Maintained operational discipline through Project Viking, successfully transitioning two product lines out of the Holliston facility to streamline the manufacturing footprint.

Growth Trajectory and Operational Efficiency

Raised full-year revenue growth guidance to 3% to 5% based on first-half momentum and expanding commercial traction in the CMT portfolio.
Revised full-year adjusted gross margin guidance down by 100 basis points to 57% to 59% to account for the ongoing mix shift toward lower-margin geographic and product segments.
Reaffirmed adjusted EBITDA growth of 6% to 10%, assuming strong Q4 flow-through over a fixed cost base and benefits from July commercial restructuring.
Projected $3 million in cost savings from Project Viking in 2027, scaling to $4 million annually thereafter as manufacturing consolidation completes.
Anticipates a stronger second half in the U.S. academic segment as NIH funding release patterns gradually improve.

Structural Changes and Risk Factors

Completed a 1-for-10 reverse stock split in March, which is retroactively reflected in all per-share financial reporting.
Inventory levels increased to support manufacturing pre-build requirements for Project Viking transitions and to improve product lead times.
Operating expenses increased by $1.2 million year-over-year due to the restoration of salaries and merit increases to normalize the cost structure.
Actively marketing the Holliston facility for sub-lease, though management does not expect a signed agreement until Q4 2026 or Q1 2027.

Q&A Session Insights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Growth drivers for electroporation and organoid product lines

Management confirmed strong double-digit growth for electroporation and year-to-date strength in Multi Channel Systems (organoids).
China demand was specifically driven by BTX electroporation, organoids, telemetry, and respiratory inhalation products.

Sales channel strategy and demand dynamics in China

Growth in China was aided by a lower baseline due to previous retaliatory tariffs and strong current demand from CROs.
The company primarily utilizes distributors to reach the Chinese market, which remains their largest revenue contributor in the region.

Academic market recovery and NIH funding outlook

The U.S. academic market is showing gradual improvement as funds are released.
Management is aggressively targeting specific pockets of funding through both direct sales teams and distribution partners to drive second-half growth.